Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. It focuses on promoting a new therapeutic approach that uses the body's natural metabolic processes to improve cellular metabolism and reverse the course of disease. The company aims to eliminate the major metabolic risk factors for cardiovascular mortality and morbidity by developing controlled metabolic accelerators (CMAs).